Remibrutinib in CSU: A Conversation With Dr. Martin Metz on New AAAAI Data
Add-on remibrutinib improved urticaria control as early as Week 2, with improvements sustained through Week 52, according to long-term results from the REMIX-1/-2 Phase 3 trials presented at the 2025 American Academy of Allergy Asthma and Immunology (AAAAI) meeting in San Diego, CA.. Novartis’ remibrutinib is a selective Bruton’s tyrosine kinase (BTK) inhibitor under investigation […]